Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(13/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(13/week)
News
United States
(421/week)
Manufacturing
(319/week)
Technology
(320/week)
Energy
(213/week)
Other Manufacturing
(264/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Trastuzumab emtansine
Nov 28, 2019
Health Canada approves Kadcyla® (trastuzumab emtansine) for the treatment of HER2-positive early breast cancer after surgery(1)
Sep 09, 2019
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
Jun 04, 2019
RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
Apr 29, 2019
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric Cancer
Mar 28, 2019
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
Mar 28, 2019
Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1
Jan 23, 2019
Antibody Drug Conjugate Market Size Worth USD 9.93 Billion By 2025: Grand View Research, Inc.
Jan 14, 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Dec 08, 2018
Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Nov 27, 2018
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
Oct 21, 2018
Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress
May 31, 2018
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
May 16, 2018
Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and U3-1402 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Mar 27, 2018
Daiichi Sankyo's HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
Mar 23, 2018
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Jan 18, 2018
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
Dec 07, 2017
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
Oct 24, 2017
Goodwin Biotechnology and For-Robin Collaborated to Generate a Unique Antibody : Drug Conjugate (ADC) that Shows Promise in Enhancing the Treatment of a Variety of Cancers
Sep 28, 2017
Antibody Drug Conjugates Market Grow at 21.82% CAGR By 2022, Analysis by Adcetris, Kadcyla and Pipeline Drugs
Sep 11, 2017
Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
Page 1
››
Latest News
Mar 29, 2024
Universal Display Corporation to Deliver Keynote Address and Sponsor ICDT 2024
Mar 29, 2024
Cepton, Inc. Reports Fourth Quarter and Full Year 2023 Results
Mar 29, 2024
Ascent Industries Reports Fourth Quarter and Full Year 2023 Results
Mar 29, 2024
Surf Air Mobility Reports Financial Results for Fourth Quarter and Full Year Ended December 31, 2023
Mar 29, 2024
Planet Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024
Mar 29, 2024
Fastenal Releases 2024 Environmental, Social, and Governance (ESG) Report
Mar 29, 2024
Danimer Scientific Announces Fourth Quarter and Full Year 2023 Results
Mar 29, 2024
CVD Equipment Corporation Reports Fourth Quarter and Fiscal Year 2023 Financial Results
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events